WS #6786

From 496 msgs · 7 key-dev

The April jobs report beat expectations significantly, with nonfarm payrolls rising 115,000 versus the 62,000 consensus estimate, while the unemployment rate held at 4.3%. However, wage growth came in softer than expected at +0.2% MoM and +3.6% YoY (vs. +0.3% and +3.8% expected). This mixed report reduces the urgency for Fed rate cuts but also alleviates some stagflation fears, creating a nuanced backdrop for equities. The Middle East conflict remains the dominant macro risk, with Iran seizing the oil tanker Ocean Koi in the Gulf of Oman and reports of smoke at Dubai Airport following alleged drone attacks. US intelligence assesses Iran retains 70% of its missile stockpile, while Trump described recent US strikes as minor and noted a ceasefire remains in effect. Secretary of State Rubio expects an Iranian response on the peace deal 'today,' keeping diplomatic hopes alive but fragile. On the corporate front, several notable earnings and strategic moves stand out: Akamai's $1.8 billion AI cloud deal, SoftBank scaling back its OpenAI margin loan by 40% due to lender pushback, Cloudflare's post-earnings selloff despite strong results, and Baidu's AI chip unit Kunlunxin targeting a $14.6 billion Hong Kong IPO. The UK local elections continue with the SNP holding Dundee City East. The narrative arc for the Middle East conflict is STABLE but at a high level of tension, with no major escalation or de-escalation in this window.

Key developments

  • April payrolls surge 115,000 vs 62,000 estimate, wage growth misses
  • Iran seizes oil tanker Ocean Koi in Gulf of Oman; drone attack reported at Dubai Airport
  • Akamai secures $1.8 billion AI cloud deal with leading frontier model provider
  • SoftBank scales back planned $10 billion OpenAI margin loan by 40% after lender pushback
  • Cloudflare sells off despite strong Q1 results as CEO announces major restructuring
  • Baidu AI chip unit Kunlunxin targets $14.6 billion Hong Kong IPO
  • Phoenix Asia Holdings surges 88% premarket after $1B ACEA Pharma acquisition